Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Abstract We report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (ORR) (RECIST v1.1). Overall surv...
Saved in:
Main Authors: | Sandip P. Patel, Eleanor Cano-Linson, Young Kwang Chae, Shiruyeh Schokrpur, Christopher D. Lao, Benjamin C. Powers, Adrienne I. Victor, Adedayo A. Onitilo, Sarah Shin, Naoko Takebe, Sara Threlkel, Christine M. McLeod, Helen X. Chen, Elad Sharon, Megan Othus, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-024-00798-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Optimal radiation dose to induce an abscopal effect by combining carbon-ion radiotherapy and anti-CTLA4 antibody
by: Liqiu Ma, et al.
Published: (2025-02-01) -
Correction: Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
Published: (2023-01-01) -
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
by: Razelle Kurzrock, et al.
Published: (2022-09-01) -
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01) -
Engineered ipilimumab variants that bind human and mouse CTLA-4
by: Brett Robison, et al.
Published: (2025-12-01)